New hybrid Closed-Loop pump could ease diabetes management
NCT ID NCT05059860
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a hybrid closed-loop insulin delivery system (Control-IQ) in 30 adults with type 1 diabetes. The system combines an insulin pump with a continuous glucose monitor that automatically adjusts background insulin. Participants used the system for 52 weeks, and researchers measured blood sugar control, time in target range, and patient wellbeing. The goal was to see if this technology is effective and acceptable for people in Scotland.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tandem Control-IQ hybrid closed-loop insulin delivery system (insulin pump + continuous glucose monitor)
What this could lead to
If successful, this system could help people with type 1 diabetes spend more time with their blood sugar in a healthy range and reduce dangerous highs and lows.
What could go wrong
This was a small, single-group study with only 30 participants, so results may not apply to everyone. The system still requires manual insulin doses at meals and is not yet routinely available in Scotland.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Professor John McKnight
Edinburgh, Lothian, EH4 2XU, United Kingdom